# Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes

> **NCT00433641** · PHASE4 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 181 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** sibutramine
- **DRUG:** sibutramine
- **DRUG:** sibutramine

## Key facts

- **NCT ID:** NCT00433641
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** 181 (ACTUAL)
- **Last updated:** 2011-03-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00433641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00433641, "Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00433641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*